Aclaris Therapeutics (ACRS) vs Altimmune (ALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Altimmune (ALT) over the past year, gaining 84.8% versus a loss of 32.3%. Over five years, ALT leads with a -77.9% price change compared with -79.8% for ACRS. Altimmune is the larger company by market cap ($517.4 million vs $500.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ALT |
|---|---|---|
| Share price | $3.40 | $2.66 |
| Market cap | $500.48M | $517.42M |
| 1-day change | -8.11% | -0.37% |
| YTD return | +12.96% | -26.32% |
| 1-year return | +84.78% | -32.32% |
| 5-year return | -79.77% | -77.85% |
| EPS (TTM) | $-0.53 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $6.44 |
| 52-week low | $1.74 | $2.56 |
| Distance from 52-week high | -48.48% | -58.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +199.41% | +543.23% |
| Average volume | 2.38M | 4.20M |
| Shares outstanding | 147.20M | 194.52M |
| Employees | 69 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ALT by 117.1 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Healthcare · Biotechnology · 69 employees
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Healthcare · Biotechnology · 57 employees
ACRS vs ALT FAQ
Which is bigger, Aclaris Therapeutics or Altimmune?
Altimmune (ALT) is larger, with a market capitalization of $517.42M compared with $500.48M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or ALT?
ACRS returned +84.78% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Altimmune in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.